Navigation Links
The Independent Committee of the Board of Directors of Tongjitang Appoints Morgan Stanley Asia Limited as Its Financial Advisor
Date:6/1/2010

SHENZHEN, China, June 1 /PRNewswire-Asia-FirstCall/ -- The Independent Committee of the Board of Directors of Tongjitang Chinese Medicines Company ("Tongjitang" or the "Company"; NYSE: TCM), comprised of the Company's three independent directors, Dr. Harry K. Genant, Mr. David R. White and Mr. Yongcun Chen (the "Independent Committee"), announced today that Morgan Stanley Asia Limited ("Morgan Stanley") has been appointed as its independent financial advisor. In addition, the Independent Committee retained Sheppard, Mullin, Richter & Hampton LLP to serve as its United States law counsel and Thorp Alberga to serve as its Cayman Islands law counsel.

Morgan Stanley will assist the Independent Committee to evaluate the previously announced proposal from Hanmax Investment Ltd. and Fosun Industrial Co., Ltd. to acquire all of the outstanding ordinary shares of the Company (including ordinary shares outstanding in the form of American Depositary Shares) not currently owned by Hanmax Investment Ltd. or Fosun Industrial Co., Ltd. If implemented, this merger transaction would, under Cayman Islands laws, result in the Company becoming a privately-held company.

About Tongjitang Chinese Medicines Company

Tongjitang Chinese Medicines Company, through its operating subsidiaries Tongjitang Pharmaceutical, Tongjitang Distribution, Tongjitang Chain Stores, Guizhou Long-Life Pharmaceutical Company Limited, Qinghai Pulante and Anhui Jingfang, is a vertically integrated specialty pharmaceutical company focused on the development, manufacturing, marketing and selling of modernized traditional Chinese medicine in China. Tongjitang's principal executive offices are located in Shenzhen, China.

Tongjitang's flagship product, Xianling Gubao, is the leading traditional Chinese medicine for the treatment of osteoporosis in China as measured by sales in Renminbi. In addition to Xianling Gubao, the Company manufactures and markets 36 other modernized traditional Chinese medicine products and 37 western medicines. Please visit http://www.tongjitang.com for more information.

    For more information, please contact:

    ICR, Inc.
     Ashley M. Ammon or Christine Duan
     Tel: +1-203-682-8200 (Investor Relations)


'/>"/>
SOURCE Tongjitang Chinese Medicines Company
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Three Studies by Independent Scientists Highlighting Pressure Cycling Technology (PCT) to be Presented this Week at the British Mass Spectrometry Societys 29th Annual Meeting
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. InterCure and Mashco Announce Launch into Independent Pharmacies in the United Kingdom
5. Mindray Announces Appointment of Dr. Jixun Lin as Independent Director
6. Roche to Nominate Independent Directors for Election at Ventanas 2008 Annual Stockholders Meeting
7. Independent Data Safety Monitoring Board Recommends Continuation of Sangarts Pivotal Phase III Trials of Hemospan(R)
8. Kiwa Fertilizers Pass Independent Tests
9. Amarin Appoints Dr. William Mason as Lead Independent Director
10. China Pharma Appoints Three Independent Non-Executive Directors
11. China Technology Appoints Deloitte Touche Tohmatsu CPA as Independent Auditor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/11/2017)... ... January 11, 2017 , ... Back pain relief technology is now available without ... for positive back pain relief for WAR members. , This spinal restoration platform boasts ... life changing for millions suffering from chronic back pain. , What A Relief ...
(Date:1/11/2017)... and BENGALURU, India , Jan. ... Biocon Ltd. (BSE code: 532523, NSE: BIOCON) today announced ... accepted Mylan,s biologics license application (BLA) for MYL-1401O, a ... This product is a proposed biosimilar to branded trastuzumab, ... The anticipated FDA goal date set under the Biosimilar ...
(Date:1/11/2017)... GAITHERSBURG, Md. , Jan. 11, 2017 /PRNewswire/ ... clinical-stage gene delivery company, announced today that its ... will present a talk entitled  "AdenoVerse™ platform for ... during the Biotech Showcase at the upcoming Phacilitate ... Miami , Florida.  Dr. Brough,s ...
(Date:1/11/2017)... (PRWEB) , ... January 11, 2017 , ... ... signed a multi-year license agreement with Poseida Therapeutics Inc, the San Diego based ... genetic data. Poseida Therapeutics selected KBioBox in order to harness KBioBox’s powerful BioEngine ...
Breaking Biology Technology:
(Date:12/22/2016)... December 22, 2016 SuperCom (NASDAQ: ... solutions for the e-Government, Public Safety, HealthCare, and Finance sectors announced ... has been selected to implement and deploy a community-based supportive services ... Northern California , further expanding its presence in the state. ... This new program, ...
(Date:12/20/2016)... N.C. and GENEVA, Dec, 20, 2016 /PRNewswire/ ... biometric data sensor technology, and STMicroelectronics ... the spectrum of electronics applications, announced today the ... development kit for biometric wearables that includes ST,s ... with Valencell,s Benchmark™ biometric sensor system. ...
(Date:12/16/2016)... MIAMI , Dec. 16, 2016   ... intuitive Identity management products and solutions and a ... announced today that it is offering seamless, integrated ... Edam security entrance products. The solutions provide IdentyTech,s ... to secure their facilities from crime and theft. ...
Breaking Biology News(10 mins):